Zulresso

Chemical Namebrexanolone
Dosage FormInjectable (intravenous; 5 mg/mL)
Drug ClassModulators
SystemNervous
CompanySage Therapeutics
Approval Year2019

Indication

  • Zulresso is indicated for the treatment of postpartum depression (PPD) in adults.
Last updated on 10/28/2020

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Zulresso (brexanolone) Prescribing Information2019Sage Therapeutics